| |
Public Act 103-0245 Public Act 0245 103RD GENERAL ASSEMBLY |
Public Act 103-0245 | SB1987 Enrolled | LRB103 25792 RLC 57149 b |
|
| AN ACT concerning criminal law.
| Be it enacted by the People of the State of Illinois,
| represented in the General Assembly:
| Section 5. The Illinois Controlled Substances Act is | amended by changing Section 204 as follows: | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | Sec. 204. (a) The controlled substances listed in this | Section are
included in Schedule I. | (b) Unless specifically excepted or unless listed in | another
schedule, any of the following opiates, including | their isomers,
esters, ethers, salts, and salts of isomers, | esters, and ethers,
whenever the existence of such isomers, | esters, ethers and salts is
possible within the specific | chemical designation: | (1) Acetylmethadol; | (1.1) Acetyl-alpha-methylfentanyl | (N-[1-(1-methyl-2-phenethyl)-
| 4-piperidinyl]-N-phenylacetamide); | (2) Allylprodine; | (3) Alphacetylmethadol, except
| levo-alphacetylmethadol (also known as levo-alpha-
| acetylmethadol, levomethadyl acetate, or LAAM); | (4) Alphameprodine; |
| (5) Alphamethadol; | (6) Alpha-methylfentanyl
| (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| propanilido) piperidine; | (6.1) Alpha-methylthiofentanyl
| (N-[1-methyl-2-(2-thienyl)ethyl-
| 4-piperidinyl]-N-phenylpropanamide); | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | (7.1) PEPAP
| (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | (8) Benzethidine; | (9) Betacetylmethadol; | (9.1) Beta-hydroxyfentanyl
| (N-[1-(2-hydroxy-2-phenethyl)-
| 4-piperidinyl]-N-phenylpropanamide); | (10) Betameprodine; | (11) Betamethadol; | (12) Betaprodine; | (13) Clonitazene; | (14) Dextromoramide; | (15) Diampromide; | (16) Diethylthiambutene; | (17) Difenoxin; | (18) Dimenoxadol; | (19) Dimepheptanol; |
| (20) Dimethylthiambutene; | (21) Dioxaphetylbutyrate; | (22) Dipipanone; | (23) Ethylmethylthiambutene; | (24) Etonitazene; | (25) Etoxeridine; | (26) Furethidine; | (27) Hydroxpethidine; | (28) Ketobemidone; | (29) Levomoramide; | (30) Levophenacylmorphan; | (31) 3-Methylfentanyl
| (N-[3-methyl-1-(2-phenylethyl)-
| 4-piperidyl]-N-phenylpropanamide); | (31.1) 3-Methylthiofentanyl
| (N-[(3-methyl-1-(2-thienyl)ethyl-
| 4-piperidinyl]-N-phenylpropanamide); | (32) Morpheridine; | (33) Noracymethadol; | (34) Norlevorphanol; | (35) Normethadone; | (36) Norpipanone; | (36.1) Para-fluorofentanyl
| (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| 4-piperidinyl]propanamide); | (37) Phenadoxone; |
| (38) Phenampromide; | (39) Phenomorphan; | (40) Phenoperidine; | (41) Piritramide; | (42) Proheptazine; | (43) Properidine; | (44) Propiram; | (45) Racemoramide; | (45.1) Thiofentanyl
| (N-phenyl-N-[1-(2-thienyl)ethyl-
| 4-piperidinyl]-propanamide); | (46) Tilidine; | (47) Trimeperidine; | (48) Beta-hydroxy-3-methylfentanyl (other name:
| N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| N-phenylpropanamide); | (49) Furanyl fentanyl (FU-F); | (50) Butyryl fentanyl; | (51) Valeryl fentanyl; | (52) Acetyl fentanyl; | (53) Beta-hydroxy-thiofentanyl; | (54) 3,4-dichloro-N-[2-
| (dimethylamino)cyclohexyl]-N-
| methylbenzamide (U-47700); | (55) 4-chloro-N-[1-[2-
| (4-nitrophenyl)ethyl]-2-piperidinylidene]-
|
| benzenesulfonamide (W-18); | (56) 4-chloro-N-[1-(2-phenylethyl)
| -2-piperidinylidene]-benzenesulfonamide (W-15); | (57) acrylfentanyl (acryloylfentanyl). | (c) Unless specifically excepted or unless listed in | another
schedule, any of the following opium derivatives, its | salts, isomers
and salts of isomers, whenever the existence of | such salts, isomers and
salts of isomers is possible within | the specific chemical designation: | (1) Acetorphine; | (2) Acetyldihydrocodeine; | (3) Benzylmorphine; | (4) Codeine methylbromide; | (5) Codeine-N-Oxide; | (6) Cyprenorphine; | (7) Desomorphine; | (8) Diacetyldihydromorphine (Dihydroheroin); | (9) Dihydromorphine; | (10) Drotebanol; | (11) Etorphine (except hydrochloride salt); | (12) Heroin; | (13) Hydromorphinol; | (14) Methyldesorphine; | (15) Methyldihydromorphine; | (16) Morphine methylbromide; | (17) Morphine methylsulfonate; |
| (18) Morphine-N-Oxide; | (19) Myrophine; | (20) Nicocodeine; | (21) Nicomorphine; | (22) Normorphine; | (23) Pholcodine; | (24) Thebacon. | (d) Unless specifically excepted or unless listed in | another
schedule, any material, compound, mixture, or | preparation which contains
any quantity of the following | hallucinogenic substances, or which
contains any of its salts, | isomers and salts of isomers, whenever the
existence of such | salts, isomers, and salts of isomers is possible
within the | specific chemical designation (for the purposes of this
| paragraph only, the term "isomer" includes the optical, | position and
geometric isomers): | (1) 3,4-methylenedioxyamphetamine
| (alpha-methyl,3,4-methylenedioxyphenethylamine,
| methylenedioxyamphetamine, MDA); | (1.1) Alpha-ethyltryptamine
| (some trade or other names: etryptamine;
| MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| 3-(2-aminobutyl)indole; a-ET; and AET); | (2) 3,4-methylenedioxymethamphetamine (MDMA); | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
| (also known as: N-ethyl-alpha-methyl-
|
| 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| and MDEA); | (2.2) N-Benzylpiperazine (BZP); | (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | (4) 3,4,5-trimethoxyamphetamine (TMA); | (5) (Blank); | (6) Diethyltryptamine (DET); | (7) Dimethyltryptamine (DMT); | (7.1) 5-Methoxy-diallyltryptamine; | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | (9) Ibogaine (some trade and other names:
| 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| indole; Tabernanthe iboga); | (10) Lysergic acid diethylamide; | (10.1) Salvinorin A; | (10.5) Salvia divinorum (meaning all parts of the | plant presently classified
botanically as Salvia | divinorum, whether growing or not, the
seeds thereof, any | extract from any part of that plant, and every compound,
| manufacture, salts, isomers, and salts of
isomers whenever | the existence of such salts, isomers, and salts of
isomers | is possible within the specific chemical designation, | derivative, mixture, or preparation of that plant, its
| seeds or extracts);
|
| (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | (12) Peyote (meaning all parts of the plant presently | classified
botanically as Lophophora williamsii
Lemaire, | whether growing or not, the
seeds thereof, any extract | from any part of that plant, and every compound,
| manufacture, salts, derivative, mixture, or preparation of | that plant, its
seeds or extracts); | (13) N-ethyl-3-piperidyl benzilate (JB 318); | (14) N-methyl-3-piperidyl benzilate; | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| (also known as N-hydroxy-alpha-methyl-
| 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | (15) Parahexyl; some trade or other names:
| 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| dibenzo (b,d) pyran; Synhexyl; | (16) Psilocybin; | (17) Psilocyn; | (18) Alpha-methyltryptamine (AMT); | (19) 2,5-dimethoxyamphetamine
| (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | (20) 4-bromo-2,5-dimethoxyamphetamine
| (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| 4-bromo-2,5-DMA); | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| Some trade or other names: 2-(4-bromo-
| 2,5-dimethoxyphenyl)-1-aminoethane;
|
| alpha-desmethyl DOB, 2CB, Nexus; | (21) 4-methoxyamphetamine
| (4-methoxy-alpha-methylphenethylamine;
| paramethoxyamphetamine; PMA); | (22) (Blank); | (23) Ethylamine analog of phencyclidine.
| Some trade or other names:
| N-ethyl-1-phenylcyclohexylamine,
| (1-phenylcyclohexyl) ethylamine,
| N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | (24) Pyrrolidine analog of phencyclidine. Some trade | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | PHP; | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | (26) 2,5-dimethoxy-4-ethylamphetamine
| (another name: DOET); | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| (another name: TCPy); | (28) (Blank); | (29) Thiophene analog of phencyclidine (some trade
| or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| 2-thienyl analog of phencyclidine; TPCP; TCP); | (29.1) Benzothiophene analog of phencyclidine. Some | trade or other names: BTCP or benocyclidine; | (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); | (30) Bufotenine (some trade or other names:
|
| 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| 3-(2-dimethylaminoethyl)-5-indolol;
| 5-hydroxy-N,N-dimethyltryptamine;
| N,N-dimethylserotonin; mappine); | (31) (Blank); | (32) (Blank); | (33) (Blank); | (34) (Blank); | (34.5) (Blank); | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | (2-methyloctan-2-yl)-6a,7, | 10,10a-tetrahydrobenzo[c]chromen-1-ol | Some trade or other names: HU-210; | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | tetrahydrobenzo[c]chromen-1-ol, its isomers, | salts, and salts of isomers; Some trade or other | names: HU-210, Dexanabinol; | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | Some trade or other names: HU-211; | (37) (Blank); | (38) (Blank); | (39) (Blank); | (40) (Blank); |
| (41) (Blank); | (42) Any compound structurally derived from | 3-(1-naphthoyl)indole or | 1H-indol-3-yl-(1-naphthyl)methane by substitution at the | nitrogen atom of the indole ring by alkyl, haloalkyl, | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl whether or not further substituted | in the indole ring to any extent, whether or not | substituted in the naphthyl ring to any extent. Examples | of this structural class include, but are not limited to, | JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185; | (43) Any compound structurally derived from | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl, whether or not further substituted | in the pyrrole ring to any extent, whether or not | substituted in the naphthyl ring to any extent. Examples | of this structural class include, but are not limited to, | JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; | (44) Any compound structurally derived from | 1-(1-naphthylmethyl)indene by substitution at the | 3-position of the indene ring by alkyl, haloalkyl, | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
| alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl whether or not further substituted | in the indene ring to any extent, whether or not | substituted in the naphthyl ring to any extent. Examples | of this structural class include, but are not limited to, | JWH-176; | (45) Any compound structurally derived from | 3-phenylacetylindole by substitution at the nitrogen atom | of the indole ring with alkyl, haloalkyl, alkenyl, | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl, whether or not further substituted | in the indole ring to any extent, whether or not | substituted in the phenyl ring to any extent. Examples of | this structural class include, but are not limited to, | JWH-167, JWH-250, JWH-251, and RCS-8; | (46) Any compound structurally derived from | 2-(3-hydroxycyclohexyl)phenol by substitution at the | 5-position of the phenolic ring by alkyl, haloalkyl, | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl, whether or not substituted in the | cyclohexyl ring to any extent. Examples of this structural | class include, but are not limited to, CP 47, 497 and its | C8 homologue (cannabicyclohexanol); | (46.1) Any compound structurally derived from |
| 3-(benzoyl) indole with substitution at the nitrogen atom | of the indole ring by an alkyl, haloalkyl, alkenyl, | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl group whether or not further | substituted in the indole ring to any extent and whether | or not substituted in the phenyl ring to any extent. | Examples of this structural class include, but are not | limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN | 48,098), and RCS-4; | (47) (Blank); | (48) (Blank); | (49) (Blank); | (50) (Blank); | (51) (Blank); | (52) (Blank); | (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine. | Some trade or other names: 2C-T-7; | (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some | trade or other names: 2C-E; | (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some | trade or other names: 2C-D; | (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some | trade or other names: 2C-C; | (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade | or other names: 2C-I; |
| (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some | trade or other names: 2C-T-2; | (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine. | Some trade or other names: 2C-T-4; | (53.7) 2,5-dimethoxyphenethylamine. Some trade or | other names: 2C-H; | (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some | trade or other names: 2C-N; | (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some | trade or other names: 2C-P; | (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. | Some trade or other names: 2C-G; | (53.11) The N-(2-methoxybenzyl) derivative of any 2C | phenethylamine referred to in subparagraphs (20.1), (53), | (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), | (53.8), (53.9), and (53.10) including, but not limited to, | 25I-NBOMe and 25C-NBOMe; | (54) 5-Methoxy-N,N-diisopropyltryptamine; | (55) (Blank); | (56) (Blank); | (57) (Blank); | (58) (Blank); | (59) 3-cyclopropoylindole with substitution at the | nitrogen atom of the indole ring by alkyl, haloalkyl, | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
| 2-(4-morpholinyl)ethyl, whether or not further substituted | on the indole ring to any extent, whether or not | substituted on the cyclopropyl ring to any extent: | including, but not limited to, XLR11, UR144, FUB-144; | (60) 3-adamantoylindole with substitution at the | nitrogen atom of the indole ring by alkyl, haloalkyl, | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl, whether or not further substituted | on the indole ring to any extent, whether or not | substituted on the adamantyl ring to any extent: | including, but not limited to, AB-001; | (61) N-(adamantyl)-indole-3-carboxamide with | substitution at the nitrogen atom of the indole ring by | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | cycloalkylethyl, aryl halide, alkyl aryl halide, | 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl, whether or not further substituted | on the indole ring to any extent, whether or not | substituted on the adamantyl ring to any extent: | including, but not limited to, APICA/2NE-1, STS-135; | (62) N-(adamantyl)-indazole-3-carboxamide with | substitution at a nitrogen atom of the indazole ring by | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | cycloalkylethyl, aryl halide, alkyl aryl halide, | 1-(N-methyl-2-piperidinyl)methyl, or |
| 2-(4-morpholinyl)ethyl, whether or not further substituted | on the indazole ring to any extent, whether or not | substituted on the adamantyl ring to any extent: | including, but not limited to, AKB48, 5F-AKB48; | (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester | with substitution at the nitrogen atom of the indole ring | by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | cycloalkylethyl, aryl halide, alkyl aryl halide, | 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl, whether or not further substituted | on the indole ring to any extent, whether or not | substituted on the quinoline ring to any extent: | including, but not limited to, PB22, 5F-PB22, FUB-PB-22; | (64) 3-(1-naphthoyl)indazole with substitution at the | nitrogen atom of the indazole ring by alkyl, haloalkyl, | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl, whether or not further substituted | on the indazole ring to any extent, whether or not | substituted on the naphthyl ring to any extent: including, | but not limited to, THJ-018, THJ-2201; | (65) 2-(1-naphthoyl)benzimidazole with substitution | at the nitrogen atom of the benzimidazole ring by alkyl, | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | aryl halide, alkyl aryl halide, | 1-(N-methyl-2-piperidinyl)methyl, or |
| 2-(4-morpholinyl)ethyl, whether or not further substituted | on the benzimidazole ring to any extent, whether or not | substituted on the naphthyl ring to any extent: including, | but not limited to, FUBIMINA; | (66) | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- | 3-carboxamide with substitution on the nitrogen atom of | the indazole ring by alkyl, haloalkyl, alkenyl, | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl, whether or not further substituted | on the indazole ring to any extent: including, but not | limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; | (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | indazole-3-carboxamide with substitution on the nitrogen | atom of the indazole ring by alkyl, haloalkyl, alkenyl, | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl, whether or not further substituted | on the indazole ring to any extent: including, but not | limited to, ADB-PINACA, ADB-FUBINACA; | (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | indole-3-carboxamide with substitution on the nitrogen | atom of the indole ring by alkyl, haloalkyl, alkenyl, | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
| 2-(4-morpholinyl)ethyl, whether or not further substituted | on the indole ring to any extent: including, but not | limited to, ADBICA, 5F-ADBICA; | (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- | 3-carboxamide with substitution on the nitrogen atom of | the indole ring by alkyl, haloalkyl, alkenyl, | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl, whether or not further substituted | on the indole ring to any extent: including, but not | limited to, ABICA, 5F-ABICA; | (70) Methyl 2-(1H-indazole-3-carboxamido)-3- | methylbutanoate with substitution on the nitrogen atom of | the indazole ring by alkyl, haloalkyl, alkenyl, | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl, whether or not further substituted | on the indazole ring to any extent: including, but not | limited to, AMB, 5F-AMB; | (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3- | dimethylbutanoate with substitution on the nitrogen
atom | of the indazole ring by alkyl, haloalkyl, alkenyl,
| cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
aryl | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl, whether or not further substituted
| on the indazole ring to any extent: including, but not
|
| limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; | (72) Methyl 2-(1H-indole-3-carboxamido)-3- | methylbutanoate with substitution on the nitrogen atom
of | the indole ring by alkyl, haloalkyl, alkenyl,
| cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl | halide, 1-(N-methyl-2-piperidinyl)methyl,
or | 2-(4-morpholinyl)ethyl, whether or not further
substituted | on the indazole ring to any extent:
including, but not | limited to, MMB018, MMB2201,
and AMB-CHMICA; | (73) Methyl 2-(1H-indole-3-carboxamido)-3,3- | dimethylbutanoate with substitution
on the nitrogen atom | of the indole ring by alkyl,
haloalkyl, alkenyl, | cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl,
whether or not further substituted | on the
indazole ring to any extent: including, but
not | limited to, MDMB-CHMICA; | (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- | indazole-3-carboxamide with
substitution on the nitrogen | atom of the indazole
ring by alkyl, haloalkyl, alkenyl, | cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl | halide,
1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl, whether or not further
substituted | on the indazole ring to any
extent: including, but not | limited to, APP-CHMINACA,
5-fluoro-APP-PINACA; | (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- |
| 3-carboxamide with substitution on
the nitrogen atom of | the indole ring by alkyl,
haloalkyl, alkenyl, | cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2-(4-morpholinyl)ethyl,
whether or not further substituted | on the indazole
ring to any extent: including, but not | limited to,
APP-PICA and 5-fluoro-APP-PICA; | (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name | 4-AcO-DMT; | (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade | name 5-MeO-MIPT; | (78) 4-hydroxy Diethyltryptamine (4-HO-DET); | (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); | (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); | (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
| (4-HO-MiPT); | (82) Fluorophenylpiperazine; | (83) Methoxetamine; | (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- | ethcathinone). | (e) Unless specifically excepted or unless listed in | another
schedule, any material, compound, mixture, or | preparation which contains
any quantity of the following | substances having a depressant effect on
the central nervous | system, including its salts, isomers, and salts of
isomers | whenever the existence of such salts, isomers, and salts of
|
| isomers is possible within the specific chemical designation: | (1) mecloqualone; | (2) methaqualone; and | (3) gamma hydroxybutyric acid. | (f) Unless specifically excepted or unless listed in | another schedule,
any material, compound, mixture, or | preparation which contains any quantity
of the following | substances having a stimulant effect on the central nervous
| system, including its salts, isomers, and salts of isomers: | (1) Fenethylline; | (2) N-ethylamphetamine; | (3) Aminorex (some other names:
| 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| salts, optical isomers, and salts of optical isomers; | (4) Methcathinone (some other names:
| 2-methylamino-1-phenylpropan-1-one;
| Ephedrone; 2-(methylamino)-propiophenone;
| alpha-(methylamino)propiophenone; N-methylcathinone;
| methycathinone; Monomethylpropion; UR 1431) and its
| salts, optical isomers, and salts of optical isomers; | (5) Cathinone (some trade or other names:
| 2-aminopropiophenone; alpha-aminopropiophenone;
| 2-amino-1-phenyl-propanone; norephedrone); | (6) N,N-dimethylamphetamine (also known as:
| N,N-alpha-trimethyl-benzeneethanamine;
|
| N,N-alpha-trimethylphenethylamine); | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | (8) 3,4-Methylenedioxypyrovalerone (MDPV); | (9) Halogenated amphetamines and
| methamphetamines - any compound derived from either
| amphetamine or methamphetamine through the substitution
| of a halogen on the phenyl ring, including, but not
| limited to, 2-fluoroamphetamine, 3-
| fluoroamphetamine and 4-fluoroamphetamine; | (10) Aminopropylbenzofuran (APB):
| including 4-(2-Aminopropyl) benzofuran, 5-
| (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
| benzofuran, and 7-(2-Aminopropyl) benzofuran; | (11) Aminopropyldihydrobenzofuran (APDB):
| including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
| 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
| 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
| and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; | (12) Methylaminopropylbenzofuran
| (MAPB): including 4-(2-methylaminopropyl)
| benzofuran, 5-(2-methylaminopropyl)benzofuran,
| 6-(2-methylaminopropyl)benzofuran
| and 7-(2-methylaminopropyl)benzofuran. | (g) Temporary listing of substances subject to emergency | scheduling.
Any material, compound, mixture, or preparation |
| that contains any quantity
of the following substances: | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| (benzylfentanyl), its optical isomers, isomers, salts,
and | salts of isomers; | (2) N-[1(2-thienyl)
methyl-4-piperidyl]-N- | phenylpropanamide (thenylfentanyl),
its optical isomers, | salts, and salts of isomers. | (h) Synthetic cathinones. Unless specifically excepted, | any chemical compound which is not approved by the United | States Food and Drug Administration or, if approved, is not | dispensed or possessed in accordance with State or federal | law, not including bupropion, structurally derived from | 2-aminopropan-1-one by substitution at the 1-position with | either phenyl, naphthyl, or thiophene ring systems, whether or | not the compound is further modified in one or more of the | following ways: | (1) by substitution in the ring system to any extent | with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or | halide substituents, whether or not further substituted in | the ring system by one or more other univalent | substituents. Examples of this class include, but are not | limited to, 3,4-Methylenedioxycathinone (bk-MDA); | (2) by substitution at the 3-position with an acyclic | alkyl substituent. Examples of this class include, but are | not limited to, 2-methylamino-1-phenylbutan-1-one | (buphedrone); or |
| (3) by substitution at the 2-amino nitrogen atom with | alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by | inclusion of the 2-amino nitrogen atom in a cyclic | structure. Examples of this class include, but are not | limited to, Dimethylcathinone, Ethcathinone, and | a-Pyrrolidinopropiophenone (a-PPP); or | Any other synthetic cathinone which is not approved by the | United States Food and Drug Administration or, if approved, is | not dispensed or possessed in accordance with State or federal | law. | (i) Synthetic cannabinoids or piperazines. Any synthetic | cannabinoid or piperazine which is not approved by the United | States Food and Drug Administration or, if approved, which is | not dispensed or possessed in accordance with State and | federal law. | (j) Unless specifically excepted or listed in another | schedule, any chemical compound which is not approved by the | United States Food and Drug Administration or, if approved, is | not dispensed or possessed in accordance with State or federal | law, and is derived from the following structural classes and | their salts: | (1) Benzodiazepine class: A fused 1,4-diazepine and | benzene ring structure with a phenyl connected to the | 1,4-diazepine ring, with any substitution(s) or | replacement(s) on the 1,4-diazepine or benzene ring, any | substitution(s) on the phenyl ring, or any combination |
| thereof. Examples of this class include but are not | limited to: Clonazolam, Flualprazolam; or | (2) Thienodiazepine class: A fused 1,4-diazepine and | thiophene ring structure with a phenyl connected to the | 1,4-diazepine ring, with any substitution(s) or | replacement(s) on the 1,4-diazepine or thiophene ring, any | substitution(s) on the phenyl ring, or any combination | thereof. Examples of this class include but are not | limited to: Etizolam. | (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17; | 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff. | 8-14-18 .)
|
Effective Date: 1/1/2024
|
|
|